Soren Charmsaz

9PUBLICATIONS
94CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|May 05, 2026
Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer.

|Jan 12, 2026
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses.

Dimitrios N Sidiropoulos, Zhehao Zhang, Jennifer N Durham

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Apr 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.

Chester Kao, Soren Charmsaz, Hua-Ling Tsai

|Mar 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.

Mari Nakazawa, Soren Charmsaz, Elsa Hallab

Pageof 2

Frequent Collaborators

9 joint publications

Elizabeth M Jaffee

7 joint publications

Nicole Gross

7 joint publications

Mark Yarchoan

7 joint publications

Won Jin Ho